Datopotamab, a project with a very similar mechanism to Trodelvy, shows impressive early data in triple-negative breast cancer.
A Her2-positive cancer is the setting for a Keytruda triplet that could influence the trial design of some immune-stimulating agents.
A phase 3 win should remind investors about other clinical-stage CXCR4 antagonists.
The new group reckons it has the most selective Tyk2 inhibitor yet. Patenting it is another issue.